A Prospective Study of Tangwang prescription in the Treatment of Non-Proliferative Diabetic Retinopathy

A Prospective Study and mechanism exploration of Tangwang prescription in the Treatment of Non-Proliferative Diabetic Retinopathy

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2022000020

Enrollment

Unknown

Registered

2022-06-20

Start date

2022-06-30

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Proliferative Diabetic Retinopathy

Interventions

Non Tangwang prescription group:Nil

Tangwang prescription group:Nil

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria for type 2 diabetic retinopathy, the degree of the disease is non-proliferative (at least one eye meet) (2) Age 30-70 years

Exclusion criteria

Exclusion criteria: (1)Other ophthalmic diseases that do not belong to diabetic retinopathy, such as non-diabetic retinopathy, uveitis, retinal detachment, optic nerve disease and high myopia with fundus lesions; (2)meet the diagnostic criteria for diabetic retinopathy, but the degree of the disease was proliferative. (3)Type 1 diabetic retinopathy.

Design outcomes

Primary

Measure	Time frame
Reduction rate and aggravation rate of diabetic retinopathy;	—

Secondary

Measure	Time frame
Blood pressure;Number of retinal microangiomas, hemorrhages, and exudates;Incidence of endpoint events;Symptom relief;Lipids;Change in the degree of macular edema;Fasting plasma glucose;	—

Countries

China

Contacts

Public ContactFengmei Lian

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

694397644@qq.com13651249262

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026